Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Biotech market activity remains robust, with recent IPOs like Parabilis and Kyverna demonstrating strong aftermarket performance despite broader geopolitical tensions and shifting policy at the Fed. The industry is simultaneously navigating the implications of the Biosecure Act, particularly following the Department of Defense’s designation of WuXi AppTec as a Chinese military company, which triggers significant legal and operational risks for firms reliant on its services. In clinical development, the focus on cancer-associated cachexia is intensifying, with Pfizer and Catalym advancing therapies targeting the GDF-15 cytokine to address both muscle wasting and tumor progression. Meanwhile, Washington remains in flux as speculation grows regarding the tenure of HHS Secretary Robert Kennedy, with potential leadership transitions at the Department of Health and Human Services expected to follow the midterm elections.